MAPT and Alzheimer disease: Until relatively recently, pharma drug discovery in the field of AD has been focused on therapies that reduce the levels of soluble or insoluble Aβ in the brain; however, numerous high-profile late-stage failures in clinical trials have resulted in a shift in focus to reducing the levels of tau in the brain far earlier in the presymptomatic stage of the disease [6].